ANTHEM · NSE
Anthem Biosciences Limited
₹951.05
+1.52% (+₹14.25)
Prev. close
₹936.8
Volume
3,29,384
Delivery %
54.8%
As of
20 Nov 2026
Price history
Analyst sentiment
No analyst stances in this range
0 analyst stances · last 90 days · one per analyst
Try a wider range.
Explore by date range →Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Initiated coverage on Anthem Biosciences with a 'buy' rating and a price target of ₹1,050 per share, implying a 20% upsi…” | Jefferies AnalysisJefferies | Anthem Biosciences | PENDING | |
| “Bullish on Anthem Bioscience, recommending to buy on dips with a target of ₹1,000+ for a 9 to 12-month investment period…” | Prashanth TapseMehta Equities Ltd | Anthem Bioscience | MISS | |
| “Recommends holding Anthem Biosciences shares for a long-term perspective, citing strong fundamentals, differentiated cap…” | Prashanth TapseMehta Equities Ltd | Anthem Biosciences | NOT TRIGGERED | |
| “Recommends a 'hold' rating on Anthem Biosciences, believing post-listing valuations are justified by strong fundamentals…” | Prashanth TapseMehta Equities Ltd | Anthem Biosciences Ltd | NOT TRIGGERED |
Market commentary · 10 · levels, conditionals, previews, macro & hedged views — context, not graded
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Nomura has initiated a 'Buy' rating on Anthem Biosciences, leading to a 4% jump in the newly listed stock. The stock is …” | Nomura AnalysisNomura Global Markets Research | Anthem Biosciences | — | |
| “Recommends buying Anthem Biosciences Ltd for the short term. The stock has shown strength after rebounding from support,…” | Riyank AroraMehta Equities | Anthem Biosciences Ltd | — | |
| “For short-term investors allotted Anthem Biosciences shares, consider booking partial profits given the substantial over…” | Mahesh M OjhaHensex Securities Pvt Ltd | Anthem Biosciences | — | |
| “Advises investors to secure partial profits in Anthem Biosciences after its healthy listing, while retaining the remaind…” | Shivani NyatiSwastika Investmart Ltd. | Anthem Biosciences | — | |
| “Anthem Biosciences is expected to list strongly today, July 21, 2025, with a likely listing price of ₹735–740, indicatin…” | Harshal DasaniINVasset PMS | Anthem Biosciences | — | |
| “Anthem Biosciences is expected to make a strong debut on the stock exchanges today, July 21, 2025. Given robust investor…” | Mahesh M OjhaHensex Securities Pvt Ltd | Anthem Biosciences | — | |
| “Advises investors to apply for the Anthem Biosciences IPO, citing the company's strong CRDMO operations, healthy net mar…” | Arun KejriwalKejriwal Research and Investment Services | Anthem Biosciences | — | |
| “Assigned a 'subscribe' tag to the Anthem Biosciences IPO, noting the company's profitable track record compared to peers…” | Anand Rathi AnalysisAnand Rathi | Anthem Biosciences | — | |
| “Bullish on Anthem Biosciences, highlighting its strength in consistent, high-value delivery, supported by a 1,200 KL rea…” | Bhavik JoshiINVasset PMS | Anthem Biosciences | — | |
| “Bullish on Anthem Biosciences, citing a strong pipeline of 16 molecules in late-stage development and global factors lik…” | Sachin JasujaCentricity WealthTech | Anthem Biosciences | — |
Fundamentals
About Anthem Biosciences Limited
Anthem Biosciences Limited operates as a contract research, development, and manufacturing organization in India, rest of Asia, North America, Europe, and internationally. It operates in two segments: Contract Manufacturing, Development & Discovery Services; and Speciality Ingredients. The company offers contract research development and manufacturing services, such as end-to-end services across the new chemical entity and new biological entity lifecycles, as well as engages in contract research, development, and manufacturing of development batches of molecules used for clinical trials up to commercial manufacturing for small molecules and biologics. It also manufactures and sells specialized fermentation-based active pharmaceutical ingredients, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars. The company was incorporated in 2006 and is based in Bengaluru, India.
Details
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Ajay Bhardwaj B.Tech., M.S
Headquarters
Bengaluru
Employees
2,282
Website
anthembio.comExchange
View on NSE ↗Key stats
Market cap
₹50,058.20 Cr
P/E ratio (TTM)
87.5
Dividend yield
0.23%
EPS (TTM)
₹10.15
Beta (1Y · daily vs NIFTY 50)
0.51
Shares float
7.19 Cr
EPS · quarter ended Jun 2026
₹2.11
Financial Performance
01 · Financials
Net income and EBITDA are omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures. Net income ÷ revenue is not drawn for FY21 and FY22 (no net income reported). Revenue for FY26: the figure the company printed, which its own totals confirm and the series' figure did not.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss — as filed
Annual
| Line item | FY25 | FY26 |
|---|---|---|
| ₹1,930.29 Cr | ₹2,280.12 Cr | |
I Revenue from operations | ₹1,844.55 Cr | ₹2,124.33 Cr |
II Other income | ₹85.73 Cr | ₹155.78 Cr |
| ₹656.87 Cr | ₹848.63 Cr | |
VI Exceptional items | — | ₹24.39 Cr |
VII Profit/(Loss) before tax (V-VI) | ₹656.87 Cr | ₹824.24 Cr |
| ₹451.26 Cr | ₹591.79 Cr | |
| ₹450.86 Cr | ₹590.23 Cr | |
1) Basic EPS | 8.07 | 10.55 |
2) Diluted EPS | 8.04 | 10.43 |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
All years: consolidated statements.
09 · Balance Sheet — as filed
Annual
| Line item | FY25 | FY26 |
|---|---|---|
| ₹2,807.58 Cr | ₹3,429.29 Cr | |
| ₹1,319.41 Cr | ₹1,626.15 Cr | |
| ₹1,488.17 Cr | ₹1,803.15 Cr | |
| ₹2,807.58 Cr | ₹3,429.29 Cr | |
| ₹2,409.86 Cr | ₹3,042.52 Cr | |
| ₹71.49 Cr | ₹61.06 Cr | |
| ₹326.23 Cr | ₹325.71 Cr |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
All years: consolidated statements.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹278.00 Cr | ₹333.00 Cr | ₹306.00 Cr | ₹140.00 Cr | ₹271.00 Cr | ₹844.00 Cr | |
Investing cash flow | — | — | ₹-376.02 Cr | ₹-221.46 Cr | ₹-146.57 Cr | ₹-701.62 Cr |
| ₹-63.00 Cr | ₹181.00 Cr | ₹64.00 Cr | ₹-77.00 Cr | ₹-136.00 Cr | ₹-40.00 Cr | |
Capital expenditure | ₹-120.00 Cr | ₹-26.00 Cr | ₹-184.00 Cr | ₹-117.00 Cr | ₹-261.00 Cr | ₹-211.00 Cr |
End cash position | — | — | ₹342.85 Cr | ₹184.36 Cr | ₹172.28 Cr | ₹274.88 Cr |
Investing cash flow, Dividends paid, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Jul 25–Dec 25(3Q) | Mar 26 | Jun 26 |
|---|---|---|---|
| Promoter | 74.69% | 74.68% | 71.42% |
| Public | 25.31% | 25.32% | 28.58% |
| Employee trusts | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Anthem Biosciences Limited | ₹48,150.66 Cr | ₹888.3 | 84.2 | 15.83 | 19.5% | 0.02 | +15.2% | +26.5% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.